A recent study reveals that people who come off popular GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight much more quickly than those who end conventional lifestyle plans.
Research printed in a leading health publication points out that while obese individuals frequently drop substantial amounts of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"Users using such medications should be cognizant of the risk of fast weight regain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
This pace of recovery implies a return to pre-treatment weight in about one and a half years.
Comparing Approaches
The study, which examined 37 of studies involving thousands of participants, compared the outcomes of the injectable medications with older methods.
Scientists point out that people who lose weight through diet and exercise typically see a slower weight regain—perhaps 100 grams monthly—post-intervention.
The Reason for the Fast Regain
Experts propose the mechanism of the jabs is key to understanding the accelerated regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls appetite.
"Long-term administration of the hormone concentrations several times higher than normal could lead to the system to produce less of its endogenous GLP-1, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement leads to hunger is unsuppressed, making overeating a significant risk."
A Chronic Issue?
Health authorities recommend the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts say that, given the significant potential of relapse, the treatment should be considered life-long.
This view is echoed by drug manufacturers, who say that the findings "highlight the long-term nature of obesity," comparing it to managing diseases like diabetes.
Patient Accounts
Individuals who have discontinued the medication describe a intense resurgence of hunger.
"I experienced a switch that goes on and you're instantly ravenous," said a patient.
This challenge is compounded if patients have not developed lasting lifestyle or habit changes during therapy.
Widespread Interest
Survey data indicate that millions of adults in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Use is greater among females than males.
- The 40s and 50s demographic shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and maintained weight loss likely depends on ongoing behavioural changes.
